Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD-2101
- Development stage
- Phase 1
- Lead developer
- Addpharma
- Modality
- Small Molecules
01
Overview
AD-2101 is a small molecule drug developed by Addpharma for the treatment of cardiovascular diseases, with a primary focus on hypertension. The drug has undergone Phase 1 clinical evaluation to assess its pharmacokinetic interactions and safety profile, particularly in combination with another investigational agent, AD-2102. As of March 2025, the highest global R&D status for AD-2101 is "Pending," indicating it has not advanced beyond early clinical development or received regulatory approval. Detailed information regarding its mechanism of action or molecular target has not been disclosed in public sources[1][2].
Beyond the preview
Go deeper on AD-2101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD-2101.